Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
TRUEinvivo® receives CE Mark for DOSEmapper Reader, automating radiotherapy dose measurement for enhanced accuracy.
Dr. Shakardokht Jafari presents DOSEmapper™ at IPEM conference after ESTRO, highlighting glass beads' innovation in dosimetry.
Innovate UK showcases TRUEinvivo® founder for Women in Innovation award, spotlighting Dr. Shakardokht Jafari's success.
TRUEinvivo wins Business Innovation of the Year Award for DOSEmapper™ technology, revolutionizing radiotherapy safety.
